Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25847823 | 0.85 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL22644543 | 0.72 | — | — | |
| SCHEMBL21690141 | 0.71 | RNPEP (0.32) | — | |
| SCHEMBL12766244 | 0.71 | RNPEP (0.32) | — | |
| SCHEMBL16449782 | 0.69 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL21690140 | 0.69 | CHRM1 (0.38) | — | |
| SCHEMBL16449784 | 0.69 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL19230446 | 0.69 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL19230437 | 0.69 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL23660856 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | SLC2A1, SLC2A4, SLC2A2 | MAPK1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.